Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Cancer Invest. 2010 May;28(4):433-42. doi: 10.3109/07357901003631098.
Aromatase inhibitors (AIs) have largely replaced tamoxifen as adjuvant hormonal therapy for postmenopausal women with early breast cancer. While tamoxifen is effective in reducing breast cancer recurrence and mortality, recent data indicate two peaks of early, mostly distant metastatic recurrences in patients receiving tamoxifen, and AIs have proven more effective in reducing recurrence. As distant recurrence has been associated with poorer survival and death, reduction in this type of early recurrence event may lead to improved survival over the long term. Recent data from major clinical trials are beginning to bear out this contention.
芳香酶抑制剂（AIs）已在很大程度上取代他莫昔芬，成为绝经后早期乳腺癌患者的辅助激素治疗药物。虽然他莫昔芬能有效降低乳腺癌复发和死亡率，但最近的数据显示，接受他莫昔芬治疗的患者存在两个早期、主要是远处转移复发的高峰，而 AIs 在降低复发方面已被证明更有效。由于远处复发与较差的生存和死亡相关，因此减少这种早期复发事件可能会导致长期生存的改善。最近来自大型临床试验的数据开始证实这一论点。
